Published in J Clin Invest on April 01, 1994
Nitric oxide and bone. Immunology (2001) 1.60
Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol (2001) 1.29
Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis (2002) 1.24
Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci U S A (1995) 1.21
Mechanisms by which exercise improves bone strength. J Bone Miner Metab (2005) 1.04
Nitric oxide. Ann Rheum Dis (1996) 0.99
Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. Proc Natl Acad Sci U S A (2000) 0.98
Morphologic evaluation and expression of matrix metalloproteinases-2 and 9 and nitric oxide during experimental periodontal disease in rat. J Mol Histol (2008) 0.96
Nitric oxide as a mediator of inflammation?-You had better believe it. Mediators Inflamm (1995) 0.94
Nitric oxide synthase is expressed in human macrophages during foreign body inflammation. Am J Pathol (1997) 0.89
Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J Bone Miner Metab (2015) 0.85
iNOS-derived nitric oxide stimulates osteoclast activity and alveolar bone loss in ligature-induced periodontitis in rats. J Periodontol (2011) 0.85
Effect of MALP-2, a lipopeptide from Mycoplasma fermentans, on bone resorption in vitro. Infect Immun (1999) 0.83
Retracted Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 0.83
Nitric oxide signaling in mechanical adaptation of bone. Osteoporos Int (2013) 0.82
Eurycoma longifolia: Medicinal Plant in the Prevention and Treatment of Male Osteoporosis due to Androgen Deficiency. Evid Based Complement Alternat Med (2012) 0.81
Anti-Inflammatory and Analgesic Effects of the Marine-Derived Compound Excavatolide B Isolated from the Culture-Type Formosan Gorgonian Briareum excavatum. Mar Drugs (2015) 0.80
Concern The effects of organic nitrates on osteoporosis: a systematic review. Osteoporos Int (2013) 0.79
Organic nitrate maintains bone marrow blood perfusion in ovariectomized female rats: a dynamic, contrast-enhanced magnetic resonance imaging (MRI) study. Pharmaceutics (2012) 0.79
Nitric Oxide-Induced Autophagy in MC3T3-E1 Cells is Associated with Cytoprotection via AMPK Activation. Korean J Physiol Pharmacol (2015) 0.79
The effects of organic nitrates on osteoporosis: a randomized controlled trial [ISRCTN94484747]. Trials (2006) 0.78
Organic nitrates for osteoporosis: an update. Bonekey Rep (2013) 0.76
Intermittent Nitrate Use and Risk of Hip Fracture. Am J Med (2016) 0.75
Nitrates and bone turnover (NABT) - trial to select the best nitrate preparation: study protocol for a randomized controlled trial. Trials (2013) 0.75
Screening for potential genes associated with bone overgrowth after mid-shaft femur fracture in a rat model. J Orthop Surg Res (2017) 0.75
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
Nitric oxide as a secretory product of mammalian cells. FASEB J (1992) 13.38
Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science (1992) 9.01
Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature (1991) 8.41
Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med (1989) 7.72
Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol (1991) 6.92
Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci U S A (1992) 4.32
Role of osteoblasts in hormonal control of bone resorption--a hypothesis. Calcif Tissue Int (1981) 3.77
Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol (1990) 3.55
Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med (1992) 3.42
Nitric oxide, a novel biologic messenger. Cell (1992) 3.04
Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun (1990) 2.31
Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol (1991) 2.07
Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med (1990) 1.81
Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun (1993) 1.73
Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A (1991) 1.50
Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res (1983) 1.38
Preferential inhibition of cytokine-stimulated bone resorption by recombinant interferon gamma. J Bone Miner Res (1986) 1.04
Differentiation kinetics of osteoclasts in the periosteum of embryonic bones in vivo and in vitro. Anat Rec (1986) 1.03
Glucocorticoids do not affect the induction of a novel calcium-dependent nitric oxide synthase in rabbit chondrocytes. Biochem Biophys Res Commun (1992) 1.02
Impaired mitogen-induced interferon-gamma production in rheumatoid arthritis and related diseases. Scand J Immunol (1988) 0.96
Inhibition of the induction of nitric oxide synthase by glucocorticoids: yet another explanation for their anti-inflammatory effects? Trends Pharmacol Sci (1991) 0.83
Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur J Nucl Med (2000) 2.80
IFN-gamma-induced L-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-alpha. J Immunol (1992) 2.73
Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology (2000) 2.51
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J Nucl Med (2001) 2.41
Parathyroid venous sampling: anatomic considerations and results in 95 patients with primary hyperparathyroidism. Br J Radiol (1980) 2.29
Clinical risk factors as predictors of postmenopausal osteoporosis in general practice. Br J Gen Pract (2001) 1.73
Sclerostin: current knowledge and future perspectives. Calcif Tissue Int (2010) 1.71
1, 25-dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. Lancet (1979) 1.71
Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun (1989) 1.64
Imaging of bacterial infections with 99mTc-labeled human neutrophil peptide-1. J Nucl Med (1999) 1.57
Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol (1996) 1.52
Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J Bone Miner Res (2002) 1.49
Nitric oxide (NO) production correlates with renal insufficiency and multiple organ dysfunction syndrome in severe sepsis. Intensive Care Med (1996) 1.49
[Prevalence of osteoporosis in postmenopausal women in family practice]. Ned Tijdschr Geneeskd (1999) 1.41
Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology (1992) 1.37
Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages. J Leukoc Biol (1999) 1.35
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) (1987) 1.33
Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol (1993) 1.32
Studies of circulating parathyroid hormone in man using a homologous amino-terminal specific immunoradiometric assay. Clin Endocrinol (Oxf) (1980) 1.29
Endogenous tumor necrosis factor alpha is required for enhanced antimicrobial activity against Toxoplasma gondii and Listeria monocytogenes in recombinant gamma interferon-treated mice. Infect Immun (1992) 1.25
Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J Clin Invest (1998) 1.25
Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis (2002) 1.24
Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone (2003) 1.24
Interferon-gamma-activated human granulocytes kill ingested Mycobacterium fortuitum more efficiently than normal granulocytes. Eur J Immunol (1990) 1.24
Interleukin-17: A new bone acting cytokine in vitro. J Bone Miner Res (1999) 1.20
Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum (1996) 1.19
Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol (2010) 1.19
Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) (1997) 1.17
Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother (2000) 1.16
Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner (1989) 1.15
Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine (2000) 1.13
Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest (1994) 1.13
Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab (1985) 1.12
Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone (1998) 1.11
Sclerostin in mineralized matrices and van Buchem disease. J Dent Res (2009) 1.11
Activation of mouse peritoneal macrophages during infection with Salmonella typhimurium does not result in enhanced intracellular killing. J Immunol (1990) 1.09
End-organ resistance to 1,25-dihydroxycholecalciferol. Lancet (1980) 1.09
Reversible resistance to the renal action of parathyroid hormone in human vitamin D deficiency. Clin Sci (Lond) (1982) 1.09
Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int (1990) 1.06
Measurement of 1,25-dihydroxycholecalciferol in man by radioimmunoassay. Clin Endocrinol (Oxf) (1979) 1.05
99mTc-antimicrobial peptides: promising candidates for infection imaging. Q J Nucl Med (2003) 1.03
Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am J Hum Genet (1995) 1.03
Rapid identification and antimicrobial susceptibility testing of Gram-positive cocci in blood cultures by direct inoculation into the BD Phoenix system. Clin Microbiol Infect (2009) 1.02
New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable discussion. Curr Med Res Opin (2008) 1.02
Binding of surfactant protein A to C1q receptors mediates phagocytosis of Staphylococcus aureus by monocytes. Am J Physiol (1994) 1.02
Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res (1994) 1.02
Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res (1995) 1.00
Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol (1994) 1.00
The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab (1990) 1.00
A frame-shift mutation in the type I parathyroid hormone (PTH)/PTH-related peptide receptor causing Blomstrand lethal osteochondrodysplasia. J Clin Endocrinol Metab (1999) 1.00
Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet (1986) 1.00
Report on osteoporosis in the European Community: current status and recommendations for the future. Working Party from European Union Member States. Osteoporos Int (1998) 0.98
Maggot secretions suppress pro-inflammatory responses of human monocytes through elevation of cyclic AMP. Diabetologia (2009) 0.98
Studies of hypoparathyroidism and pseudohypoparathyroidism. Q J Med (1978) 0.97
A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone (2002) 0.97
Quantitative immunocytochemical characterization of mononuclear phagocytes. I. Monoblasts, promonocytes, monocytes, and peritoneal and alveolar macrophages. Cell Immunol (1987) 0.96
The prevalence of low bone mineral density in Dutch perimenopausal women: the Eindhoven perimenopausal osteoporosis study. Osteoporos Int (1998) 0.95
Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine (1999) 0.94
Inhibition of hBD-3, but not hBD-1 and hBD-2, mRNA expression by corticosteroids. Biochem Biophys Res Commun (2001) 0.93
Saponin promotes rapid identification and antimicrobial susceptibility profiling of Gram-positive and Gram-negative bacteria in blood cultures with the Vitek 2 system. Eur J Clin Microbiol Infect Dis (2012) 0.93
Bone metabolism in rheumatoid arthritis; relation to disease activity. Br J Rheumatol (1993) 0.92
Intravenous injection of interferon-gamma inhibits the proliferation of Listeria monocytogenes in the liver but not in the spleen and peritoneal cavity. Immunology (1992) 0.91
Co-trimoxazole in chronic brucellosis: a two-year follow-up study. Br Med J (1975) 0.91
Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int (1999) 0.91
Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment. J Clin Endocrinol Metab (1987) 0.91
Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J Endocrinol Invest (2005) 0.91
Spine radiographs to improve the identification of women at high risk for fractures. Osteoporos Int (2008) 0.90
Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats. J Endocrinol (1998) 0.90
Increased production of nitric oxide correlates with viral load and activation of mononuclear phagocytes in HIV-infected patients. Scand J Infect Dis (1996) 0.90
Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol (2003) 0.90
Bone mineral density in ambulant, non-steroid treated female patients with rheumatoid arthritis. Clin Exp Rheumatol (1993) 0.90
Quantification of adherent and nonadherent cells cultured in 96-well plates using the supravital stain neutral red. Anal Biochem (1993) 0.89
Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum (2004) 0.89
Yops of Yersinia enterocolitica inhibit receptor-dependent superoxide anion production by human granulocytes. Infect Immun (1999) 0.89
Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab (1995) 0.89
Transforming growth factor-beta suppresses interferon-gamma-induced toxoplasmastatic activity in murine macrophages by inhibition of tumour necrosis factor-alpha production. Parasite Immunol (2001) 0.88
Pulmonary surfactant inhibits activation of human monocytes by recombinant interferon-gamma. Immunology (1994) 0.88
Effect of apocynin on the induction of ulcerative lesions in rat skin injected with tubercle bacteria. Int J Immunopharmacol (1992) 0.88
Effects of monomethylfumarate on dendritic cell differentiation. Br J Dermatol (2006) 0.88
Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res (1996) 0.87
Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int (1988) 0.87
Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone (1998) 0.86
Metabolites of vitamin D in human vitamin-D deficiency: effect of vitamin D3 or 1,25-dihydroxycholecalciferol. Lancet (1980) 0.86
Facial dysmorphia, parathyroid and thymic dysfunction in the father of a newborn with the DiGeorge complex. Eur J Pediatr (1989) 0.86
Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). Vaccine (1999) 0.86
The characterization, origin, and kinetics of skin macrophages during inflammation. J Invest Dermatol (1985) 0.86
Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer (1987) 0.86
Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract (2010) 0.86
Stimulation of the intracellular killing of Staphylococcus aureus by human monocytes mediated by Fc gamma receptors I and II. Eur J Immunol (1993) 0.86
IL-1alpha, IL-1beta, IL-6, and TNF-alpha steady-state mRNA levels analyzed by reverse transcription-competitive PCR in bone marrow of gonadectomized mice. J Bone Miner Res (1998) 0.85
Regulation of parathyroid hormonelike protein production in cultured normal and malignant keratinocytes. J Invest Dermatol (1992) 0.84
1alpha-hydroxyvitamin D3 in the long-term management of hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf) (1977) 0.84
Ligand-dependent activation of the melanocortin 5 receptor: cAMP production and ryanodine receptor-dependent elevations of [Ca(2+)](I). Biochem Biophys Res Commun (2002) 0.84